Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC for COVID-19-Induced ARDS
NCT04905836Phase 2Unknown
- Sponsor
- Sorrento Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing COVI-MSC with Placebo (2 arms). Primary endpoints: All-cause mortality rate at Day 28, Incidence of all adverse events at Day 90 and 3 more. Status: unknown.
02
Drugs
COVI-MSC
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04905836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905836.